US · Healthcare · Diagnostics & Research
EPS came in at 4.78 against a street estimate of 4.65 — a beat of 2.8%.
Analysts rate Labcorp Holdings Inc. a buy (12 buy, 5 hold, 0 sell out of 17) with an average price target of $382.25.
CONFIDENT LH beat Q2 expectations with 5.8% revenue growth, 70bp margin expansion, and 15% EPS growth. Raised FY26 guidance on strength in specialty testing and Central Labs. Organic diagnostics growth of 3.6% outpaced market; early development stabilizing. Q2 2026 Call focused on enterprise and segments; no regional breakdown provided. Analysts probed organic-growth composition, early-development margin durability, and competitive positioning. Management emphasized quality-driven strategy, specialty/hospital focus over volume chase, and visibility into H2 through strong backlogs and study-start normalization. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.10% |
| Vanguard Capital Management, LLC | 6.60% |
| Victory Capital Management Inc. | 5.96% |
| State Street Corp | 4.81% |
| Vanguard Portfolio Management, LLC | 4.53% |
| Boston Partners Global Investors, Inc | 3.76% |
| Allspring Global Investments Holdings, LLC | 2.75% |
| Geode Capital Management, LLC | 2.70% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 OTHER NOTABLE POINTS • Labcorp Holdings Inc. announced that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on | 2026-11-04 |
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $3,810.0 million, up from $3,563.5 million in the third quarter of 2025. • Nine-month 2026 revenue | 2026-10-30 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $3.81 billion, up 6.9% from $3.56 billion in Q3 2025. • Diluted EPS was $3.22 versus $3.12, up 3.3%. Adjusted | 2026-10-28 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Labcorp Holdings Inc. declared a cash dividend of $0.72 per common share. • The dividend is payable on December 11, 2026. • Inve | 2026-10-21 |
| Reg FD disclosure · Q3 2026 HEADLINE NUMBERS • Labcorp Holdings Inc. announced it will release its third-quarter 2026 financial results before the market opens on Wednesday, Oct | 2026-09-30 |
| Reg FD disclosure · Q3 2026 LABCORP HOLDINGS INC. - FORM 8-K SUMMARY GUIDANCE & OUTLOOK • Long-term outlook (2026-2029) reaffirmed despite CMS payment rate concerns announced S | 2026-09-22 |
| Reg FD disclosure · Q3 2026 LABCORP HOLDINGS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics disclosed in this Form 8-K filing itself • Company reaffir | 2026-09-10 |
| Reg FD disclosure · Q3 2026 LABCORP HOLDINGS INC. - DOCUMENT SUMMARY HEADLINE NUMBERS • No financial metrics provided – This is a regulatory disclosure document (Form 8-K) anno | 2026-08-28 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.72 / share ex-date Nov 24, 2026 · pay Dec 11, 2026 | 2026-11-24 |
| Dividend | $0.72 / share ex-date Aug 28, 2026 · pay Sep 11, 2026 | 2026-08-28 |
| Dividend | $0.72 / share ex-date May 29, 2026 · pay Jun 11, 2026 | 2026-05-29 |
| Dividend | $0.72 / share ex-date Feb 27, 2026 · pay Mar 12, 2026 | 2026-02-27 |
| Dividend | $0.72 / share ex-date Nov 26, 2025 · pay Dec 11, 2025 | 2025-11-26 |
| Announcement | Date |
|---|---|
| Board declared a $0.72 per-share cash dividend payable December 11, 2026 Labcorp’s board declared a quarterly cash dividend of $0.72 per common share. Investors who own shares as of the November 24, 2026 record date will receive the dividend on December 11, 2026. | 2026-10-21 |
| Reaffirms 2026-2029 long-term outlook on revenue, margin, and EPS growth Labcorp released an 8-K disclosure regarding preliminary 2027-2029 Medicare payment rates from CMS under the PAMA program. The company views these rates as unfavorable, citing steep annual p | 2026-09-22 |
| Reaffirmed 2026 guidance and provided long-term financial outlook through 2029 Labcorp Holdings Inc. held its 2026 Investor Day on September 10, 2026, where management presented its growth strategy, innovation roadmap, and financial outlook through 2029. The company re | 2026-09-10 |
| Board declares cash dividend of $0.72 per share Labcorp Holdings Inc. announced a quarterly cash dividend of $0.72 per share, payable on September 11, 2026, to shareholders of record as of August 28, 2026. This is a routine dividend decla | 2026-07-10 |
| Board declares cash dividend of $0.72 per share Labcorp Holdings Inc. announced a quarterly cash dividend of $0.72 per share, payable on June 11, 2026, to shareholders on record as of May 29, 2026. This is a routine dividend declaration b | 2026-04-09 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Labcorp Holdings Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.